A talk by Dr. Dan Roden: "Genomes, Hype, and a Realistic Pathway to Personalized Medicine"
Roden is widely-recognized for his expertise in clinical, genetic, cellular, and molecular basis of arrhythmia susceptibility and variability responses to arrhythmia therapies. Over the past decade, he has led Vanderbilt's broader efforts in pharmacogenomics discovery and implementation. Currently, he directs the Vanderbilt DNA databank, BioVU and the John A. Oates Institute for Experimental Therapeutics. Roden also serves as Principal Investigator for the Vanderbilt sites of the National Institutes of Health's Pharmacogenomics Research Network and the National Human Genome Research Institute's Electronic Medical Records and Genomics network.